Low-level night-time light therapy for age-related macular degeneration (ALight): study protocol for a randomized controlled trial

BACKGROUND: Age-related macular degeneration (AMD) is the leading cause of blindness among older adults in the developed world. The only treatments currently available, such as ranibizumab injections, are for neovascular AMD, which accounts for only 10 to 15% of people with the condition. Hypoxia ha...

Descripción completa

Detalles Bibliográficos
Autores principales: McKeague, Claire, Margrain, Tom H, Bailey, Clare, Binns, Alison M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4227140/
https://www.ncbi.nlm.nih.gov/pubmed/24965385
http://dx.doi.org/10.1186/1745-6215-15-246

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4227140/
https://www.ncbi.nlm.nih.gov/pubmed/24965385
http://dx.doi.org/10.1186/1745-6215-15-246

Ejemplares similares